Kakehashi to Address "Gaps in Medical Touchpoints" for Outpatients with Cancer Using AMED-Adopted Project, Launching Large-Scale Demonstration Connecting Hospitals, Pharmacies, and Patients

Kakehashi Inc. (Headquarters: Minato-ku, Tokyo; President and Representative Director: Yutaka Nakao; CEO and Representative Director: Takashi Nakagawa; hereinafter "the Company") is pleased to announce the completion of the foundational system development for a commissioned project adopted under the "Platform for Realizing Social Implementation of Preventive and Health-Promoting Research and Development (Healthcare Service Practical Application Research Project)" for Reiwa 7 (2025) promoted by the Japan Agency for Medical Research and Development (AMED).

In conjunction with this, the clinical research project "PRO-MISE Trial" utilizing this system has officially launched, with the registration of target patients at participating hospitals and the commencement of demonstration operations by the end of June.

This project aims to build a system for continuous follow-up of patients undergoing outpatient cancer chemotherapy by digitally connecting hospitals, pharmacies, and patients using PHR (Personal Health Records) that centrally manage individual health and medical information. By early detection of symptom changes and side effects between outpatient visits, and connecting these to appropriate medical interventions, the project seeks to resolve the issue of "gaps in medical touchpoints."

The Company has developed a dedicated system leveraging the foundation cultivated through its patient follow-up system "Pocket Musubi." This demonstration, utilizing the new system, aims to collect data from approximately 900 cases over 8-10 months, marking a large-scale initiative in Japan. We will contribute to the social implementation of medical DX and PHR utilization promoted by the government.

1. Background of Planning and Social/On-site Issues to be Resolved

In Japan's medical field, as the shift from inpatient-centered care to outpatient and home healthcare progresses, the existence of "gaps in medical touchpoints" occurring between outpatient visits has become an issue.

It is difficult for healthcare professionals to grasp the patient's condition outside of their appointments. This can lead to a decrease in patient adherence (the state of proactively continuing treatment) and delays in healthcare providers recognizing signs of side effects, potentially increasing the risk of severe illness or unplanned hospitalization.

Particularly in outpatient cancer chemotherapy, early intervention for side effects and changes in physical condition significantly impacts prognosis. However, with ongoing staff shortages in medical settings, performing continuous patient follow-up with limited resources alone places a burden on the field, necessitating the creation of new systems that do not rely solely on human resources.

2. Overview and Objectives of "PRO-MISE Trial"

This project aims to socially implement a monitoring and follow-up platform for patients undergoing cancer chemotherapy utilizing PHR. The Company has previously promoted initiatives for patient monitoring in outpatient treatment for cancer and heart failure (PHARE-Onc-01 Study, PHARE-ONC 02 RT Study, PHARE-HF Study) as a demonstration operator for the Ministry of Economy, Trade and Industry's "Reiwa 6 (2024) Healthcare Industry Foundation Advancement Promotion Project (Demonstration Survey Project for Promoting PHR Utilization in Medical Institutions)." This current demonstration will further expand upon previous knowledge and achievements, verifying the validity of PHR utilization in actual clinical settings.

In this demonstration, aiming for the social implementation of PHR, approximately 900 cases will be monitored for 24 weeks each to verify the usefulness of ePRO. This large-scale, multi-institutional collaborative PHR verification is one of the largest initiatives of its kind in Japan (※), ensuring high reliability for social implementation. (※As of June 2026, according to our research).

The system, now completed, automatically sends questions to patients about their symptoms once a week, and the response results are sent to medical institutions as a report. Furthermore, these response results can be centrally managed by the hospital. This system promotes information sharing between hospitals and pharmacies, reducing the workload for both. Moreover, by enabling timely and appropriate early intervention, it is expected to contribute to the prevention of severe illness and unplanned hospitalizations in patients.

3. Future Outlook

Through this demonstration, the Company will first prove the clinical validity of PHR utilization in outpatient cancer chemotherapy and establish an environment where patients can complete their treatment optimally. Simultaneously, by promoting information sharing between hospitals and pharmacies, we will develop a new medical provision model that compensates for the shortage of healthcare professionals' resources and alleviates on-site burdens through the power of digital technology.

Moving forward, we aim to broadly deploy and expand the digital collaboration infrastructure and high-precision monitoring mechanisms cultivated in this large-scale demonstration to various disease areas. By creating an environment where patients can continue treatment with peace of mind during their medication period, it will lead to the prevention of severe illness, and in the future, it is expected to contribute to the optimization of medical costs for the nation as a whole.

Kakehashi will continue to aim for the construction of a sustainable next-generation medical infrastructure by promoting information sharing between hospitals, pharmacies, and patients, and realizing a state where medical care is continuously connected even during outpatient periods.

● About "Pocket Musubi"

"Pocket Musubi" is a patient follow-up system available via a LINE app, designed to provide a pharmacy experience that makes patients want to "visit this pharmacy again." It offers features that allow patients to use pharmacies with peace of mind and convenience, such as a "Follow-up During Medication Period Function" that screens patients who need follow-up based on their medication status, enabling pharmacists to take appropriate actions without burden, and a "Prescription Submission Function" that allows patients to shorten waiting times at the pharmacy by sending an image of their prescription before arrival.

● About Our Company

Kakehashi Inc. is a health-tech startup aiming to rebuild Japan's medical system. We leverage technology to achieve better medical care for patients in a sustainable manner for medical sites. Currently, in addition to our cloud-based electronic prescription record "Musubi," we develop and provide multiple products, covering over 17,000 pharmacies nationwide as a group. We support maximizing treatment effects through patient follow-up during medication periods and visualizing and stabilizing the supply of pharmaceuticals in the market. We are building a platform to realize better medical care in collaboration with various stakeholders, including pharmacies and medical institutions.

<Company Overview>

Company Name: Kakehashi Inc.

Established: March 30, 2016

Location: Sumitomo Fudosan Hibiya Bldg. 5F, 2-8-6 Nishi-Shimbashi, Minato-ku, Tokyo

URL: https://www.kakehashi.life/

<Contact Information for Inquiries>

Kakehashi Inc. Public Relations

Email: [email protected]

Phone: 03-6825-2058